Journal of Rheumatic Diseases

Cited by CrossRef (6)

  1. Young Ho Lee, Gwan Gyu Song. Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis. Pharmacogenomics J 2023;23:210
    https://doi.org/10.1038/s41397-023-00308-9
  2. Sandeep Yadav, C Balakrishnan, Gurmeet Mangat, Jatin Kothari. Rituximab as add-on therapy in patients with resistant lupus nephritis who have failed induction or maintenance therapy with other agents: A real-world experience from a single center in Mumbai. Lupus 2024;33:88
    https://doi.org/10.1177/09612033231219354
  3. Chang-Hee Suh. Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis. J Rheum Dis 2022;29:59
    https://doi.org/10.4078/jrd.2022.29.2.59
  4. Young Ho Lee, Gwan Gyu Song. Efficacy and safety of tacrolimus versus mycophenolate mofetil as induction treatment and low-dose tacrolimus as treatment for lupus nephritis: a meta-analysis. Z Rheumatol 2023;82:754
    https://doi.org/10.1007/s00393-022-01313-2
  5. Young Ho Lee, Gwan Gyu Song. Treatment of active systemic lupus erythematosus with baricitinib: A meta-analysis of randomized controlled trials. Lupus 2023;32:1493
    https://doi.org/10.1177/09612033231208842
  6. Qing Yan, Jianwen Liu, Xianming Long, Chenmin Wu, Diantian Lin, Yanfang Wu, Fei Gao, Li Zhang, Ning Chen. Tofacitinib therapy in systemic lupus erythematosus with arthritis: a retrospective study. Clin Rheumatol 2024;43:3139
    https://doi.org/10.1007/s10067-024-07103-2